Advertisement

A multi-institutional outcomes analysis of patients with relapsed or refractory DLBCL treated with ibrutinib

Allison M. Winter, Daniel J. Landsburg, Anthony R. Mato, Krista Isaac, Francisco J. Hernandez-Ilizaliturri, Nishitha Reddy, Stephen Smith, Mazyar Shadman, Mitchell R. Smith, Paolo Caimi, Deepa Jagadeesh and Brian T. Hill

Article Figures & Data

Figures

Tables

  • Table 1.

    Characteristics of patients treated with ibrutinib according to subtype

    CharacteristicAll patients (n = 54)Non-GCB (n = 24)GCB (n = 11)RT (n = 13)Unknown (n = 6)P
    Age at diagnosis, y, median (range)62 (38-88)61 (38-88)61 (47-79)61 (47-80)68 (40-71).97
    Sex, no. (%)
     Men33 (61)15 (63)4 (36)9 (69)5 (83).27
     Women21 (39)9 (37)7 (64)4 (31)1 (17)
    IPI at diagnosis, no. (%)
     Low14 (26)5 (21)4 (36)4 (31)1 (17).78
     Low intermediate11 (20)7 (29)1 (9)2 (15)1 (17)
     High intermediate13 (24)7 (29)1 (9)3 (23)2 (33)
     High16 (30)5 (21)5 (46)4 (31)2 (33)
    Number of prior treatments
     Median3333.04.61
     Range1-111-82-81-112-5
    Prior transplant,* no. (%)17 (31)6 (25)5 (46)3 (23)3 (50).42
    CNS disease at diagnosis, no. (%)6 (11)4 (17)0 (0)1 (8)1 (17).53
    • CNS, central nervous system; IPI, International Prognostic Index.

    • * All transplants were autologous except 2, who received allogeneic transplants (1 with GCB subtype and 1 with non-GCB subtype).